ACI
EGRX

AMP Capital Investors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

AMP Capital Investors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,766
Closed -$397K – 1257
2020
Q1 		$397K Buy
+8,766
New +$440K ﹤0.01% 926

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AMP Capital Investors's EGRX Position: Q2 2020 in Review

AMP Capital Investors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 8,766 shares — an estimated $397K sold.

AMP Capital Investors first reported a position in EGRX in Q1 2020 and held it in 1 quarter. The position peaked at $397K in Q1 2020. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

  • AMP Capital Investors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • AMP Capital Investors sold 8,766 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $397K.
  • AMP Capital Investors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • AMP Capital Investors's Eagle Pharmaceuticals, Inc. position peaked at $397K in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on AMP Capital Investors's 13F filing for Q2 2020, filed 14 Aug 2020.